These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 17076599)
1. Delivery of lysosomal enzymes for therapeutic use: glucocerebrosidase as an example. Grabowski GA Expert Opin Drug Deliv; 2006 Nov; 3(6):771-82. PubMed ID: 17076599 [TBL] [Abstract][Full Text] [Related]
2. Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. Van Patten SM; Hughes H; Huff MR; Piepenhagen PA; Waire J; Qiu H; Ganesa C; Reczek D; Ward PV; Kutzko JP; Edmunds T Glycobiology; 2007 May; 17(5):467-78. PubMed ID: 17251309 [TBL] [Abstract][Full Text] [Related]
3. Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease. Sun Y; Liou B; Chu Z; Fannin V; Blackwood R; Peng Y; Grabowski GA; Davis HW; Qi X EBioMedicine; 2020 May; 55():102735. PubMed ID: 32279952 [TBL] [Abstract][Full Text] [Related]
4. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Lieberman RL; Wustman BA; Huertas P; Powe AC; Pine CW; Khanna R; Schlossmacher MG; Ringe D; Petsko GA Nat Chem Biol; 2007 Feb; 3(2):101-7. PubMed ID: 17187079 [TBL] [Abstract][Full Text] [Related]
16. Mechanism of glucocerebrosidase activation and dysfunction in Gaucher disease unraveled by molecular dynamics and deep learning. Romero R; Ramanathan A; Yuen T; Bhowmik D; Mathew M; Munshi LB; Javaid S; Bloch M; Lizneva D; Rahimova A; Khan A; Taneja C; Kim SM; Sun L; New MI; Haider S; Zaidi M Proc Natl Acad Sci U S A; 2019 Mar; 116(11):5086-5095. PubMed ID: 30808805 [TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. Maegawa GH; Tropak MB; Buttner JD; Rigat BA; Fuller M; Pandit D; Tang L; Kornhaber GJ; Hamuro Y; Clarke JT; Mahuran DJ J Biol Chem; 2009 Aug; 284(35):23502-16. PubMed ID: 19578116 [TBL] [Abstract][Full Text] [Related]
18. Plant-based oral delivery of β-glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease. Shaaltiel Y; Gingis-Velitski S; Tzaban S; Fiks N; Tekoah Y; Aviezer D Plant Biotechnol J; 2015 Oct; 13(8):1033-40. PubMed ID: 25828481 [TBL] [Abstract][Full Text] [Related]
19. The Production of Human β-Glucocerebrosidase in Naphatsamon U; Ohashi T; Misaki R; Fujiyama K Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29986415 [TBL] [Abstract][Full Text] [Related]
20. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Shaaltiel Y; Bartfeld D; Hashmueli S; Baum G; Brill-Almon E; Galili G; Dym O; Boldin-Adamsky SA; Silman I; Sussman JL; Futerman AH; Aviezer D Plant Biotechnol J; 2007 Sep; 5(5):579-90. PubMed ID: 17524049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]